Myungmoon acquires approval of its stomach and head & neck cancer treatment as ‘first generic’

Published: 2017-09-26 16:43:19

Updated: 2017-09-26 16:43:19

Myungmoon Pharm, which has recently concentrated its capacity into the anticancer drug business, acquired approval of its stomach cancer and head & neck cancer treatments, ‘Tego Cap 20 and Tego Cap 25,’ from the Ministry of Food and Drug Safety(MFDS) from the 31^st of August through a strategic partnership with Taiwanese ‘Lotus Pharma.’ (commercialized on 1 November)

According to Myungmoon Phar...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.